As the organiser of a support group for patients suffering from Giant Cell Arteritis (GCA), I see firsthand the struggles and pain that these individuals endure. GCA is a rare, autoimmune disease that causes inflammation of the arteries, which can result in blindness and stroke. The drug Actemra (tocilizumab) has been proven to be an effective treatment, reducing symptoms and improving quality of life.

However, current PBS funding only covers 12 months' worth of this crucial medication. This is insufficient as GCA is a chronic condition requiring long-term management. According to research published in The New England Journal of Medicine, most patients require treatment with Actemra for at least two years to maintain remission (NEJM, 2017).

By limiting funding to just one year, we are denying GCA patients the necessary care they need to manage their condition effectively. We urge the government to extend its funding beyond this period so that those living with GCA can continue receiving their much-needed medication without financial burden.

Please sign this petition urging Mark Butler MP (Department of Health and Aged Care) to extend funding for Actemra beyond 12 months for all Giant Cell Arteritis patients.